By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Roche and Evotec today announced a three-year agreement directed at biomarker discovery for use with oncology drugs under development by Roche.

Under the terms of the deal, Evotec will use its PhosphoScout platform for the discovery of protein phosphorylation biomarkers that may be used to determine the efficacy of targeted cancer drugs in patients and for dosing decisions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.